口服给药的MK-4482在叙利亚仓鼠模型中抑制新冠病毒复制。
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
作者信息
Rosenke Kyle, Hansen Frederick, Schwarz Benjamin, Feldmann Friederike, Haddock Elaine, Rosenke Rebecca, Barbian Kent, Meade-White Kimberly, Okumura Atsushi, Leventhal Shanna, Hawman David W, Ricotta Emily, Bosio Catharine M, Martens Craig, Saturday Greg, Feldmann Heinz, Jarvis Michael A
机构信息
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
出版信息
Nat Commun. 2021 Apr 16;12(1):2295. doi: 10.1038/s41467-021-22580-8.
The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
新冠疫情在世界许多地区仍在持续蔓延。一种有效的抗SARS-CoV-2病毒药物，若能口服并用于高风险暴露后的预防，将对控制新冠疫情大有裨益。在此，我们表明，口服核苷类似物MK-4482在叙利亚仓鼠模型中可抑制SARS-CoV-2复制。在高风险暴露模型中，于感染前12小时或感染后12小时开始给药，均可观察到MK-4482对动物体内SARS-CoV-2复制的抑制作用。这些数据支持了MK-4482在高风险暴露后控制人类SARS-CoV-2感染以及治疗新冠患者方面的潜在效用。
Zotero 插件